1999
DOI: 10.1038/sj.bmt.1702032
|View full text |Cite
|
Sign up to set email alerts
|

Practical considerations in the use of tacrolimus for allogeneic marrow transplantation

Abstract: Summary:Tacrolimus has been shown to be more effective than cyclosporine for prevention of acute graft-versus-host disease (GVHD). A number of transplant centers have therefore adopted tacrolimus as standard prophylaxis, but with additional experience, current management of tacrolimus differs from that in the clinical studies. Therefore, a consensus conference was convened to assess the current practices. For prevention of GVHD, conference participants recommended administering tacrolimus at 0.03 mg/kg/day (by… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
62
0

Year Published

2001
2001
2020
2020

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 64 publications
(62 citation statements)
references
References 7 publications
0
62
0
Order By: Relevance
“…1,2 Adverse events such as renal and hepatic toxicity have been associated with increased tacrolimus blood concentrations after HSCT. 3,4 Such adverse reactions may be preventable with therapeutic drug monitoring and coordinated dose adjustments.…”
Section: Introductionmentioning
confidence: 99%
“…1,2 Adverse events such as renal and hepatic toxicity have been associated with increased tacrolimus blood concentrations after HSCT. 3,4 Such adverse reactions may be preventable with therapeutic drug monitoring and coordinated dose adjustments.…”
Section: Introductionmentioning
confidence: 99%
“…14,15 Nephrotoxicity (SCr Ͼ2.0 mg/dl) occurs in 32-92.6% of patients undergoing related or unrelated donor HCT. [2][3][4][5]7,13,16 In one study, the risk of developing nephrotoxicity (SCr Ͼ2 mg/dl) was increased by 84.4% when the mean tacrolimus concentration was Ͼ20 ng/ml.…”
mentioning
confidence: 99%
“…At least 2 comparative studies reported a significantly lower risk of a GvHD by administering Tacrolimus in lieu of CyA [13,14] . Other advantages include a reduction in morbidity, and in the overall need for aggressive immunosuppressive regimens in the group receiving Tacrolimus [12] . A disadvantage of Tacrolimus is the need to administer as 24 h continous infusion should the oral application form be contraindicated (e.g.…”
Section: Discussionmentioning
confidence: 99%